Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS

Shoreline Biome to Launch New DNA Isolation Kit at Miami Winter Symposium 2020


FARMINGTON, Conn., Jan. 24, 2020 /PRNewswire-PRWeb/ -- Shoreline Biome, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, today announced that the company will debut a novel new DNA isolation kit at the Miami Winter Symposium 2020, taking place January 26-29.

The new product, Shoreline Biome's Rapid Prep kit, is a fast and easy-to-use kit designed for the efficient and unbiased isolation of high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40KB from Gram-negative and Gram-positive bacterial and fungal cultures. The ssDNA output is ideal for downstream PCR applications targeting specific microbial, fungal, or mammalian genes of interest.

Additionally, the company will present a poster at the Symposium in collaboration with researchers from West Virginia University School of Medicine.

Shoreline Biome's poster presentation, "Sustained Gut Dysbiosis Following Experimental Sepsis in Alzheimer's Disease Transgenic Mice," is scheduled for Monday, January 27, from 1:30?2:30 p.m. The poster presents research conducted by Allison L. Brichacek, Divine C. Nwafor, Dawn Gratalo, Mark D. Driscoll, and Candice M. Brown. The session will be presented by Brichacek, a student in Brown's lab at West Virginia University School of Medicine.

Shoreline Biome will also be an exhibitor at the Symposium.

The Miami Winter Symposium 2020 will be held January 26?29, 2020, at the Hyatt Regency Miami in Miami, Fla. The symposium is dedicated to molecular mechanisms linking the microbiome and human health. It includes an international line-up of renowned speakers; award lectures by the "stars" of microbiome research; focused sessions on hot topics in microbiome research; the latest international research; and networking opportunities with key research teams from around the world. For more information about the Miami Winter Symposium 2020, visit miamiwintersymposium.com.

About Shoreline Biome:
Characterizing the human microbiome and analyzing its role in human health and disease are priority goals for researchers around the world. Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level. With Shoreline Biome products, all it takes is three easy steps: lyse, purify, and amplify. Shoreline Biome's easy-to-use companion analysis software and comprehensive reference database enables straightforward strain-level identification and quantitation of all bacteria in the sample. To learn more, visit shorelinebiome.com.

 

SOURCE Shoreline Biome


These press releases may also interest you

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...



News published on and distributed by: